A Tailored Approach to Diagnosis and Early Treatment in Patients with Duchenne Muscular Dystrophy: A Real-World View of Quality of Life
Released On
June 30, 2023
Expires On
December 31, 2024
Media Type
Internet
Completion Time
30 minutes
Specialty
Neurology, Pediatrics
Topics
Muscular Dystrophy, Pediatrics
This activity is supported by an educational grant from Sarepta Therapeutics, Inc.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of Neurologists, NPs & PAs in neurology settings, and other treaters of DMD.
Program Overview
Join pediatric neurologist Dr. Aravindhan Veerapandiyan (Dr. Panda) from the Arkansas Children’s Hospital for an overview of best practices in the management of Duchenne muscular dystrophy. Through this presentation, viewers can gain a greater understanding of DMD pathophysiology, identify key signs suggestive of a diagnosis, and describe the benefits and limitations associated with the current standard of care. In the second half of this presentation, Dr. Veerapandiyan examines emerging therapeutic strategies poised to transform the management of Duchenne muscular dystrophy, which in recent years has transformed from a uniformly fatal pediatric disease into a more manageable, chronic condition. Interspersed throughout this video is the perspective of Amanda – a mother and caregiver of a child who lives with DMD. With this added voice, viewers can better appreciate the challenges faced by children with DMD and the need for coordinated, multidisciplinary care to optimize patient outcomes.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Use expert-guided treatment strategies for patients with Duchenne muscular dystrophy.
Faculty
Aravindhan Veerapandiyan, MD
Pediatric Neurologist
Arkansas Children's Hospital
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Disclosures of Financial Relationships
The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:
Aravindhan Veerapandiyan, M.D., is a consultant for Biogen, Novartis, AveXis, Sarepta Therapeutics, PTC Therapeutics, Scholar Rock, Fibrogen, AMO pharma, Pfizer, Muscular Dystrophy Association, Parent Project Muscular Dystrophy, and France Foundation. He has received grant and research funding from Pfizer, Sarepta, RegenxBio, PPMD, MDA, AMO, Teva, Lilly, Edgewise, Capricor and Octapharma.
Bassam A. Bassam, M.D., FAAN
Professor of Neurology
University of South Alabama
Mobile, Alabama
Bassam A. Bassam, M.D., has received speaker honoraria from Argenx SE.
Michael R. Page, PharmD, RPh
Independent Medical Director/Medical Writer
Plainsboro, New Jersey
Dr. Page is a consultant for BioCentric, Inc. and American Medical Communications, Inc.
None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The CME Institute of Physicians Postgraduate Press, Inc., requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions please contact: [email protected] .